Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Jerald Sadoff(University of Maryland, Baltimore), Macaya Douoguih(Johnson & Johnson (Netherlands)), Georgi Shukarev(University of Maryland, Baltimore), Hanneke Schuitemaker(Johnson & Johnson (Israel)), Johan Vingerhoets(University of Maryland, Baltimore), Gert C. Scheper(University of Maryland, Baltimore), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Paul Goepfert(University of Maryland, Baltimore), Edith Swann(National Institutes of Health), Kathleen M. Neuzil(Center for Global Development), Frank Struyf(Janssen (Belgium)), Dan H. Barouch(Beth Israel Deaconess Medical Center), Jeffrey J. Stoddard(University of Maryland, Baltimore), Karin Hardt(University of Maryland, Baltimore), Ilse Van Dromme(University of Maryland, Baltimore), An Vandebosch(University of Maryland, Baltimore), Lawrence Corey(Fred Hutch Cancer Center), Martin Ryser(University of Maryland, Baltimore), Javier Ruiz‐Guiñazú(University of Maryland, Baltimore), Merlin L. Robb(University of Maryland, Baltimore), Jerome Custers(Janssen (Netherlands)), Carla Truyers(University of Maryland, Baltimore), Mary Marovich(University of Maryland, Baltimore), Bart Spiessens(University of Maryland, Baltimore), Vicky Cárdenas(University of Maryland, Baltimore), Johan Van Hoof(University of Maryland, Baltimore), John J. Treanor(University of Maryland, Baltimore), Mathieu Le Gars(University of Maryland, Baltimore), Glenda Gray(South African Medical Research Council)

New England Journal of Medicine

February 9, 2022

Cited by 250

|New England Journal of Medicine|2021|2.6k

|Nature Reviews Disease Primers|2018|1.5k

|The Lancet|2004|1.3k

|New England Journal of Medicine|1990|1.3k

|New England Journal of Medicine|1996|1.3k

Related Papers